BD PROJECTS

• Insights

  Morphic’s stock prices soar by 75%! Eli Lilly invests an additional $3.2 billion in the autoimmune field

  2024年7月10日
• Insights

  Exchanging a CAR-T therapy for 18% of the shares, the decision-making of Innovent Biologics

  2024年7月9日
• Bio News

  Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease

  2024年7月8日
• Bio News

  The “Comprehensive Chain Support Plan for the Development of Innovative Medicines” has been reviewed and approved, and the industry has responded enthusiastically!

  2024年7月6日
• Insights

  8 Key Highlights! What Do Global Pharma Industry BD and M&A Trends Forecast for 2024?

  2024年7月5日
• Insights

  Gilead | A Ray of Hope for the Highly Anticipated TROP2 ADC Trodelvy

  2024年7月3日
• Anti infection/viral

  A PD-L1 siRNA that Can Boost Immune Response for CHB Functional Cure 【Product for Licensing】

  2024年7月3日
• Bio News

  Lilly’s Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer’s Disease

  2024年7月3日
• Bio News

  Radionetics Oncology Enters Into Strategic Agreement With Lilly on its proprietary GPCR targeting small molecule radiopharmaceuticals

  2024年7月2日
• Insights

  What is the Current Landscape of Obesity Drug Development in China?

  2024年7月2日